Tvardi Therapeutics Business Summary

Tvardi Therapeutics, Inc. (TVRD) is a clinical-stage biopharmaceutical company that operates on a research-and-development business model, generating value through the advancement of its proprietary STAT3 inhibitor platform. Following its 2025 merger with Cara Therapeutics, the company transitioned to a public listing on the NASDAQ, primarily funding operations through equity financing, strategic collaborations, and legacy royalty streams. Tvardi’s primary business segments are focused on oncology and chronic fibrosis, with its lead candidate, TTI-101, currently in Phase 2 clinical trials for hepatocellular carcinoma (HCC) and idiopathic pulmonary fibrosis (IPF). The company’s competitive landscape includes major players such as Gilead Sciences, Corbus Pharmaceuticals, and Prelude Therapeutics; Tvardi distinguishes itself as a specialized leader in oral, small-molecule STAT3 inhibition, aiming to address high-unmet-need indications where STAT3 serves as a central driver of disease pathogenesis. The company was founded by Dr. David J. Tweardy and Dr. Ronald DePinho, both of whom possess deep clinical pedigrees from the MD Anderson Cancer Center. The leadership team is headed by CEO and President Imran Alibhai, Ph.D., a former investment banker and Senior VP at DNAtrix, supported by Chief Financial Officer Dan Conn and Chief Medical Officer John Kauh, M.D., an oncologist with extensive experience in regulatory drug submissions. Tvardi’s Board of Directors is chaired by Sujal Shah, the former CEO of CymaBay Therapeutics who oversaw its $4.3 billion acquisition by Gilead, and includes notable industry veterans such as Michael Wyzga (formerly CFO of Genzyme) and Susan Shiff. The company maintains a strong institutional investor base, including the AIM-HI Accelerator Fund and various healthcare-focused venture capital firms.